Asset profile

Enasidenib

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved — Acute Myeloid Leukemia

Regulatory approval supersedes design-level evidence grading — the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

How the evidence outlook works ↗

Upcoming events

(9 total)

Estimated primary-completion dates from ClinicalTrials.gov — registry estimates, never confirmed readout dates; they can move as trials progress.

2027 (7)
January 2027 (1)
Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2027-01-11 · NCT03728335 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

February 2027 (1)
Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2027-02-28 · NCT03383575 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

March 2027 (1)
Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2027-03-31 · NCT06672146 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

April 2027 (1)
Phase 3Acute Myeloid LeukemiaActive not recruiting
Est. primary completion 2027-04-17 · NCT03839771 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

September 2027 (2)
Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2027-09-20 · NCT03683433 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2027-09-30 · NCT05401097 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

November 2027 (1)
Phase 1/2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2027-11-29 · NCT04774393 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2028 (1)
December 2028 (1)
Phase 1/2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2028-12 · NCT03013998 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2029 (1)
May 2029 (1)
Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2029-05-15 · NCT05564390 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

See the full readout calendar ↗

All registered studies

Research

Unlock the complete ClinicalTrials.gov registry

Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.

Competitive landscape

Research

Unlock the competitor landscape

Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.